Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

ted to be comparable with 2007, a reflection of the significant decline in Protonix revenue, and gross margin is expected to continue to be approximately 72% to 74%. Selling, general and administrative expenses are expected to decrease approximately 2%, excluding the effect of foreign exchange, and research and development expenses are projected to be flat. Net interest is expected to be expense in 2008, not income as in 2007, due to declining interest rates, and other income is expected to decline substantially in 2008 primarily due to a decrease in royalty income. The tax rate is expected to be approximately 29% to 31%.

In 2008, Wyeth will begin Project Impact -- a company-wide program designed to redefine the Company's business model to facilitate long-term growth, as well as address short-term fiscal challenges.

Results of Operations

The comparative results of operations are as follows:

(In thousands except per share amounts)

(UNAUDITED)

Three Months Ended Full Year Ended

12/31/2007 12/31/2006 12/31/2007 12/31/2006

Net Revenue $5,763,526 $5,220,179 $22,399,798 $20,350,655

Cost of Goods Sold 1,691,418 1,490,920 6,313,687 5,587,851

Selling, General and

Administrative

Expenses 1,882,476 1,796,036 6,753,698 6,501,976

Research and Development

Expenses 882,466 911,094 3,256,785 3,109,060

Interest Income, Net (17,071) (6,524) (90,511) (6,646)

Other Income, Net(1) (38,795) (65,951) (290,543) (271,490)

Income Before Income

Taxes 1,363,032 1,094,604 6,456,682 5,429,904

Provision for Income

Taxes 345,602 239,189 1,840,722 1,233,198

Net Income
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... NJ (PRWEB) April 16, 2015 ... Dr. Joseph V. Gulfo to become the Executive ... Entrepreneurship. Simultaneously, FDU announced the kick-off of the ... program spearheaded by Dr. Gulfo, under the Rothman ... College of Business) and in collaboration with FDU’s ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... the American College of Cardiology 57th Annual ... Scientific ... VRML ), a molecular diagnostics company, presented data from a,study ... the diagnosis of peripheral artery disease,(PAD). The research suggests that such ...
... Expansion of Remergent Skincare Line, FREEPORT, N.Y., ... focused on the development and sale of skincare,products ... a $5,million investment round led by existing investor ... The new capital is being used to ...
... Sirion Therapeutics, Inc., a,privately held ophthalmic-focused ... from two Phase 3 clinical trials of,Durezol(TM) ... in,the treatment of postoperative ocular inflammation. The ... Korenfeld, MD during the American Society of,Cataract ...
Cached Biology Technology:Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 2Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 3Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 3
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... A team of scientists led by the Department of Energy,s ... is publishing this week the first genome sequence of an ... in a major gap among the vertebrates sequenced to date. ... far fewer other vertebrates," said co-author Richard Harland, UC Berkeley ...
... not just sap-sucking, plant-destroying enemies of agriculture. In fact, ... traits, according to a study that appears in the ... First, aphids are, so far, the only ... The aphid,s pigment-producing ability is unique to the animal ...
... A new study from the University of Rochester finds ... brain that gives it language capabilities above and beyond those ... regions of the brain, each designed to accomplish different primitive ... on the type of grammar used in forming a given ...
Cached Biology News:Scientists report first genome sequence of frog 2Scientists report first genome sequence of frog 3Scientists report first genome sequence of frog 4Aphids evolved special, surprising talents 2Sign language study shows multiple brain regions wired for language 2Sign language study shows multiple brain regions wired for language 3
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
Biology Products: